Place of fulvestrant in the treatment of patients with metastatic luminal Her2-negative breast cancer

Hormone therapy alone or in combination with targeted agents (CDK4/6 inhibitors, alpelisib, everolimus) is currently the standard treatment of metastatic luminal Her2-negative breast cancer. Aromatase inhibitors and fulvestrant are main hormone agents. Fulvestrant belongs to a special class antiestrogens – selective estrogen receptor degraders (SERD) does not have agonist activity, unlike tamoxifen. In addition, efficacy depend on presence ESR1 mutations tumor. The aromatase CDK4/6 first-line patients hormone-sensitive tumors, that is, progression more than 1 year after end adjuvant therapy. Whereas ± used for disease hormonal 1st line as 2nd inhibitor choice PIK3CA mutation difficult. This article presents clinical example use alpelisib patient secondary resistance (progression inhibitors) palbociclib. Carrying out provided long-term (for 14 months) stabilization tumor process.